Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Depreciation & Amortization (CF) (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $237000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) changed 0.42% to $237000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $910000.0, a 5.01% decrease, with the full-year FY2024 number at $942000.0, up 16.3% from a year prior.
  • Depreciation & Amortization (CF) was $237000.0 for Q3 2025 at Centessa Pharmaceuticals, up from $226000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $246000.0 in Q4 2023 to a low of $28000.0 in Q1 2022.
  • A 4-year average of $170866.7 and a median of $230000.0 in 2024 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 640.62% in 2023, then fell 9.58% in 2025.
  • Centessa Pharmaceuticals' Depreciation & Amortization (CF) stood at $36000.0 in 2022, then skyrocketed by 583.33% to $246000.0 in 2023, then decreased by 6.5% to $230000.0 in 2024, then rose by 3.04% to $237000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Depreciation & Amortization (CF) are $237000.0 (Q3 2025), $226000.0 (Q2 2025), and $217000.0 (Q1 2025).